Skip Navigation


NDT Advance Access originally published online on July 26, 2006
Nephrology Dialysis Transplantation 2006 21(11):3052-3054; doi:10.1093/ndt/gfl439
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/11/3052    most recent
gfl439v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Luft, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luft, F. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule*

Friedrich C. Luft

Franz Volhard Clinic, Medical Faculty of the Charité, HELIOS Klinikum-Berlin, Max Delbrück Center for Molecular Medicine, Berlin, Germany

Correspondence and offprint requests to: Friedrich C. Luft, Franz Volhard Clinic, Medical Faculty of the Charité, HELIOS Klinikum-Berlin, Max Delbrück Center for Molecular Medicine, Berlin Buch, Wiltberg Strasse 50, 13125 Berlin, Germany. Email: luft@charite.de

Keywords: pre-eclampsia; soluble endoglin

The first 10% of the full text of this article appears below.

Pre-eclampsia is a devastating disease of late (after week 20) pregnancy. The condition features hypertension, proteinuria, premature labor, haemolysis, liver abnormalities, thrombocytopenia (HELLP syndrome), seizures (eclampsia) and death [1]. Both mothers and children, if they survive delivery, can expect subsequent increased cardiovascular risk in the future. Pre-eclampsia affects about 5% of the pregnancies in affluent societies; in the rest of the world, the incidence is higher. Suffice it to say, pre-eclampsia is a major world health problem.

The group led by Anand Karumanchi et al. [2] has made major contributions in terms of our understanding pre-eclampsia. They showed that pre-eclampsia is associated with a circulating aberrant splice variant of the vascular endothelial growth factor (VEGF) receptor fms-like tyrosine kinase (Flt). This receptor is also an important . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. M. Lopez-Novoa
Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia
Nephrol. Dial. Transplant., March 1, 2007; 22(3): 712 - 714.
[Full Text] [PDF]